Conversation with The Cancer Letter Lilly’s PACE Continuous Innovation Indicators Visualize Progress and Value in Research October 30, 2015Vol.41 No.40By Matthew Bin Han Ong
Free How Much is a Drug Worth? A Provocative Model Puts a Price on Benefit October 30, 2015Vol.41 No.40By Matthew Bin Han Ong
Free ACS Recommends First Mammogram at 45, Transitioning to Biennial Screening After 55 October 23, 2015Vol.41 No.39By Paul Goldberg
Conversation with The Cancer LetterFree Wender: ACS Guideline Hinges on Shared Decision Making October 23, 2015Vol.41 No.39By Paul Goldberg
FreeGuest Editorial Brawley on Mammography: What We Know, What We Don’t Know, and What We Believe October 23, 2015Vol.41 No.39
Free Vice President Biden Calls For National Committment to Cancer Research October 23, 2015Vol.41 No.39
340B Guidance to Scale Back Discounts; Hospitals Will Need to Show Patient Benefit October 16, 2015Vol.41 No.38By Matthew Bin Han Ong
Judge Nixes HRSA’s Second Attempt To Enact Orphan Drug Discounts in 340B October 16, 2015Vol.41 No.38By Matthew Bin Han Ong
